The FDA approved GARZULYS (insulin aspart-fsan) from Emerge Bioscience under biologics licence application BLA 761497 on 15 September 2026. The public application record names the product, the sponsor and the nonproprietary name, and nothing further.
The four-letter suffix on the nonproprietary name marks this as a biologic licensed with a distinguishing suffix rather than a new molecular entity. For a prescriber, the practical consequence of another rapid-acting aspart product reaching a market is on price and supply rather than on how the insulin is used — the pharmacology is aspart.
What the record does not say is whether it carries an interchangeability designation, which is what would determine substitution at the pharmacy counter in the US. It also says nothing about India: there is no CDSCO position in this record, and the product's availability here is unknown. Do not tell a patient it is coming.
- Recognise -fsan as a suffix distinguishing the product, not a different insulin.
- Do not assume pharmacy-level substitutability; that needs an interchangeability designation the approval record does not state.
- Indian availability and CDSCO status are unknown — say so rather than estimating.
- Dose conversion from another aspart product is not a reason to change titration targets.
Why it matters
Supply and price of rapid-acting analogues is the constraint most Indian patients actually meet, so who else is licensed to make one is worth tracking.
Don't overread it
An application entry in the FDA database is an administrative record, not a safety finding or a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free